BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Chen L, He X, Fan L, Yang G, Chen X, Lin X, DU L, Li Z, Ye H, Mao Y, Zhao X, Wei Y. Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer 2008;18:652-9. [PMID: 17892458 DOI: 10.1111/j.1525-1438.2007.01070.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ezzeldeen Y, Swidan S, ElMeshad A, Sebak A. Green Synthesized Honokiol Transfersomes Relieve the Immunosuppressive and Stem-Like Cell Characteristics of the Aggressive B16F10 Melanoma. Int J Nanomedicine 2021;16:5693-712. [PMID: 34465990 DOI: 10.2147/IJN.S314472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wang TE, Lai YH, Yang KC, Lin SJ, Chen CL, Tsai PS. Counteracting Cisplatin-Induced Testicular Damages by Natural Polyphenol Constituent Honokiol. Antioxidants (Basel) 2020;9:E723. [PMID: 32784851 DOI: 10.3390/antiox9080723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. Int J Mol Sci 2020;21:E455. [PMID: 31936832 DOI: 10.3390/ijms21020455] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 24.0] [Reference Citation Analysis]
4 Eliaz I, Weil E. Intravenous Honokiol in Drug-Resistant Cancer: Two Case Reports. Integr Cancer Ther 2020;19:153473542092261. [DOI: 10.1177/1534735420922615] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ong CP, Lee WL, Tang YQ, Yap WH. Honokiol: A Review of Its Anticancer Potential and Mechanisms. Cancers (Basel) 2019;12:E48. [PMID: 31877856 DOI: 10.3390/cancers12010048] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
6 Zhu M, Li B, Ma H, Huang X, Wang H, Dai Y, Li Y, Li HM, Wu CZ. Synthesis and in vitro antitumor evaluation of honokiol derivatives. Bioorg Med Chem Lett 2020;30:126849. [PMID: 31831382 DOI: 10.1016/j.bmcl.2019.126849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Eliaz I, Raz A. Pleiotropic Effects of Modified Citrus Pectin. Nutrients 2019;11:E2619. [PMID: 31683865 DOI: 10.3390/nu11112619] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
8 Liu HT, Wang TE, Hsu YT, Chou CC, Huang KH, Hsu CC, Liang HJ, Chang HW, Lee TH, Tsai PS. Nanoparticulated Honokiol Mitigates Cisplatin-Induced Chronic Kidney Injury by Maintaining Mitochondria Antioxidant Capacity and Reducing Caspase 3-Associated Cellular Apoptosis. Antioxidants (Basel) 2019;8:E466. [PMID: 31600935 DOI: 10.3390/antiox8100466] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
9 Lin D, Yan Z, Chen A, Ye J, Hu A, Liu J, Peng J, Wu X. Anti-proliferative activity and structure-activity relationship of honokiol derivatives. Bioorg Med Chem 2019;27:3729-34. [PMID: 31278004 DOI: 10.1016/j.bmc.2019.06.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Banik K, Ranaware AM, Deshpande V, Nalawade SP, Padmavathi G, Bordoloi D, Sailo BL, Shanmugam MK, Fan L, Arfuso F, Sethi G, Kunnumakkara AB. Honokiol for cancer therapeutics: A traditional medicine that can modulate multiple oncogenic targets. Pharmacological Research 2019;144:192-209. [DOI: 10.1016/j.phrs.2019.04.004] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 31.0] [Reference Citation Analysis]
11 Lee JS, Sul JY, Park JB, Lee MS, Cha EY, Ko YB. Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway. Int J Mol Med 2019;43:1969-78. [PMID: 30864681 DOI: 10.3892/ijmm.2019.4122] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
12 Rauf A, Patel S, Imran M, Maalik A, Arshad MU, Saeed F, Mabkhot YN, Al-showiman SS, Ahmad N, Elsharkawy E. Honokiol: An anticancer lignan. Biomedicine & Pharmacotherapy 2018;107:555-62. [DOI: 10.1016/j.biopha.2018.08.054] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
13 Abdelhamid AS, Zayed DG, Helmy MW, Ebrahim SM, Bahey-el-din M, Zein-el-dein EA, El-gizawy SA, Elzoghby AO. Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine 2018;13:2637-56. [DOI: 10.2217/nnm-2018-0196] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
14 Achkar IW, Abdulrahman N, Al-Sulaiti H, Joseph JM, Uddin S, Mraiche F. Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. J Transl Med. 2018;16:96. [PMID: 29642900 DOI: 10.1186/s12967-018-1471-1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 87] [Article Influence: 19.8] [Reference Citation Analysis]
15 Yang J, Pei H, Luo H, Fu A, Yang H, Hu J, Zhao C, Chai L, Chen X, Shao X, Wang C, Wu W, Wan L, Ye H, Qiu Q, Peng A, Wei Y, Yang L, Chen L. Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways. Oncotarget 2017;8:915-32. [PMID: 27906672 DOI: 10.18632/oncotarget.13687] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
16 Huang KJ, Kuo CH, Chen SH, Lin CY, Lee YR. Honokiol inhibits in vitro and in vivo growth of oral squamous cell carcinoma through induction of apoptosis, cell cycle arrest and autophagy. J Cell Mol Med 2018;22:1894-908. [PMID: 29363886 DOI: 10.1111/jcmm.13474] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 8.5] [Reference Citation Analysis]
17 Guillermo-Lagae R, Santha S, Thomas M, Zoelle E, Stevens J, Kaushik RS, Dwivedi C. Antineoplastic Effects of Honokiol on Melanoma. Biomed Res Int 2017;2017:5496398. [PMID: 28194418 DOI: 10.1155/2017/5496398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
18 Ji N, Jiang L, Deng P, Xu H, Chen F, Liu J, Li J, Liao G, Zeng X, Lin Y, Feng M, Li L, Chen Q. Synergistic effect of honokiol and 5-fluorouracil on apoptosis of oral squamous cell carcinoma cells. J Oral Pathol Med 2017;46:201-7. [DOI: 10.1111/jop.12481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
19 Hahm ER, Singh KB, Singh SV. c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle 2016;15:2309-20. [PMID: 27341160 DOI: 10.1080/15384101.2016.1201253] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
20 Zuo GY, Zhang XJ, Han J, Li YQ, Wang GC. In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). BMC Complement Altern Med 2015;15:425. [PMID: 26627468 DOI: 10.1186/s12906-015-0938-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
21 Hahm ER, Karlsson AI, Bonner MY, Arbiser JL, Singh SV. Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate 2014;74:408-20. [PMID: 24338950 DOI: 10.1002/pros.22762] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
22 Kumar A, Kumar Singh U, Chaudhary A. Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities. Future Med Chem 2013;5:809-29. [PMID: 23651094 DOI: 10.4155/fmc.13.32] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
23 He Z, Subramaniam D, Zhang Z, Zhang Y, Anant S. Honokiol as a Radiosensitizing Agent for Colorectal cancers. Curr Colorectal Cancer Rep 2013;9. [PMID: 24307888 DOI: 10.1007/s11888-013-0191-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
24 Liu J, Tang M, Lai H, Dong Y, Xie C, Ye H, Ma L, Qiu N, Li Y, Cai L, Chen L. Identification of metabolites of honokiol in rat urine using 13C stable isotope labeling and liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of Chromatography A 2013;1295:48-56. [DOI: 10.1016/j.chroma.2013.03.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
25 Pan XY, Li X, Che YC, Li HY, Li X, Zhang Y, Yang X. Overexpression of claudin-4 may be involved in endometrial tumorigenesis. Oncol Lett 2013;5:1422-6. [PMID: 23599806 DOI: 10.3892/ol.2013.1198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
26 Zahedi P, Yoganathan R, Piquette-miller M, Allen C. Recent advances in drug delivery strategies for treatment of ovarian cancer. Expert Opinion on Drug Delivery 2012;9:567-83. [DOI: 10.1517/17425247.2012.665366] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
27 Zamboni WC, La-beck NM. Carrier-Mediated and Targeted Cancer Drug Delivery. Oxidative Stress in Cancer Biology and Therapy 2012. [DOI: 10.1007/978-1-61779-397-4_21] [Reference Citation Analysis]
28 Xie Y, Long Q, Wu Q, Shi S, Dai M, Liu Y, Liu L, Gong C, Qian Z, Wei Y, Zhao X. Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite. RSC Adv 2012;2:7759. [DOI: 10.1039/c2ra20612a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kim J, Jeong S, Kim B, Yun S, Choi DY, Kim S. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells: Melatonin potentiates cisplatin-induced apoptosis in SK-OV-3. Journal of Pineal Research 2012;52:244-52. [DOI: 10.1111/j.1600-079x.2011.00935.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
30 Yanbo L, Lili L, Weigao S, He G, Xiaodong G. Panoxadiol saponin enhances apoptotic effect of cisplatin on DU145 prostatic cancer cells. Proceedings 2011 International Conference on Human Health and Biomedical Engineering 2011. [DOI: 10.1109/hhbe.2011.6028037] [Reference Citation Analysis]
31 Li C, Chao LK, Wang S, Chang H, Tsai M, Fang S, Liao P, Ho C, Chen S, Cheng W, Chiang C, Kuo Y, Hua K, Hsu IC. Honokiol inhibits LPS-induced maturation and inflammatory response of human monocyte-derived dendritic cells. J Cell Physiol 2011;226:2338-49. [DOI: 10.1002/jcp.22576] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
32 Liang S, Fu A, Zhang Q, Tang M, Zhou J, Wei Y, Chen L. Honokiol inhibits HepG2 migration via down-regulation of IQGAP1 expression discovered by a quantitative pharmaceutical proteomic analysis. Proteomics 2010;10:1474-83. [PMID: 20127691 DOI: 10.1002/pmic.200900649] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
33 Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 2009;11:1139-48. [PMID: 19203212 DOI: 10.1089/ars.2009.2440] [Cited by in Crossref: 231] [Cited by in F6Publishing: 208] [Article Influence: 19.3] [Reference Citation Analysis]
34 Luo Y, Xu Y, Chen L, Hu J, Peng C, Xie D, Shi J, Huang W, Xu G, Peng M, Han J, Li R, Yang S, Wei Y. Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol. Bioorg Med Chem Lett 2009;19:4702-5. [PMID: 19589678 DOI: 10.1016/j.bmcl.2009.06.071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
35 Hu J, Chen LJ, Liu L, Chen X, Chen PL, Yang G, Hou WL, Tang MH, Zhang F, Wang XH. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Exp Mol Med. 2008;40:617-628. [PMID: 19116447 DOI: 10.3858/emm.2008.40.6.617] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
36 Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, Wang YS, Li J, Chen P, Tang MH. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009;124:2709-2718. [PMID: 19219913 DOI: 10.1002/ijc.24244] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
37 Ainbinder D, Protokin R, Chaouat M, Touitou E. Effect of honokiol and 5-FU on non-melanoma skin cancer cells. Journal of Drug Delivery Science and Technology 2009;19:283-7. [DOI: 10.1016/s1773-2247(09)50053-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Luo Y, Xu Y, Chen L, Luo H, Peng C, Fu J, Chen H, Peng A, Ye H, Xie D, Fu A, Shi J, Yang S, Wei Y. Preparative purification of anti-tumor derivatives of honokiol by high-speed counter-current chromatography. Journal of Chromatography A 2008;1178:160-5. [DOI: 10.1016/j.chroma.2007.11.072] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]